Unlocking Early Diagnosis of Brain Disorders Through Liquid Biopsies

**Early Diagnosis of Brain Disorders Using Extracellular Vesicles** Researchers at Harvard, led by David Walt, Ph.D., have made a significant breakthrough in the early detection of brain disorders like Parkinson's (PD) and Alzheimer's Disease (AD) through what's known as 'liquid biopsies'. Traditionally, brain lesions characteristic of these diseases could only be detected posthumously through invasive brain biopsies. However, Walt's team has honed a method using blood samples to isolate and analyze extracellular vesicles (EVs), tiny sacs released by brain cells. **The Challenge of Extracellular Vesicle Analysis** A key challenge in EV research has been determining whether specific biomarker molecules are encapsulated within EVs or are simply attached to their surface. The Harvard team addressed this by enzymatically removing surface-bound proteins, enabling precise measurement of proteins contained within EVs. They utilized this enhanced protocol to identify ⍺-synuclein, a protein linked to PD, in blood samples. **Technical Advances and Discoveries** The team integrated this advancement with a new ultra-sensitive assay to measure a phosphorylated form of ⍺-synuclein, which correlates with PD progression. Their findings, published in PNAS, showed an enrichment of the pathological form of ⍺-synuclein inside EVs, suggesting its potential as an early biomarker for PD. With support from philanthropic organizations such as the Chan Zuckerberg Initiative and the Michael J. Fox Foundation, the team’s methodology combines advanced techniques like size exclusion chromatography (SEC) with ultra-sensitive assays that identify and quantify EV-specific biomarkers. **Impact and Future Directions** Their work not only advances the ability to diagnose brain disorders early but opens avenues for using EVs in clinical diagnostics. The discovery that EVs can protect proteins from degradation offers insights into maintaining biomarkers' integrity during disease progression. As the team refines their methods, they are approaching a new era where non-invasive diagnostics could significantly improve outcomes for patients with neurodegenerative disorders.